
The analyst fair value estimate for Iovance Biotherapeutics has shifted from US$9.33 to US$10.00 per share, reflecting a fresh round of updated models. Recent research points to Amtagvi revenue trends, margin progression, and the potential impact of upcoming data such as IOV-LUN-202 as key reasons behind the new cluster of price targets in the US$10 to US$15 range. Read on to see how these moves fit into the broader analyst narrative and how to track the next set of updates. Analyst Price...






















